TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15496274

Group type: EXPERIMENTAL
Intervention: Growth factor priming using filgrastim (G‐CSF) and sagramostim (GM‐CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment regimens without growth factor priming
Number of subjects: 0
Study: 12352780

Group type: EXPERIMENTAL
Intervention: Calming music
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Calming music and hand massage simultaneously
Number of subjects: 68

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 68
Study: 9836318

Group type: EXPERIMENTAL
Intervention: Task arrangement involving mobility
Number of subjects: 3

Group type: COMPARATOR
Intervention: Task arrangement involving sedentariness
Number of subjects: 3
Study: 8009691

Group type: EXPERIMENTAL
Intervention: Incision, curettage, and suture under antibiotic cover
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marsupialization
Number of subjects: 0
Study: 2529814

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 59
Study: 54336

Group type: EXPERIMENTAL
Intervention: Vi antigen at dosages of 25, 50, and 100 mug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vi antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard typhoid vaccine (lot 6A)
Number of subjects: 0
Study: 30803000

Group type: EXPERIMENTAL
Intervention: Deep learning approach using 3 T CEST data to predict 9.4 T CEST signals; low saturation power of B1 = 0.6 µT.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Deep learning approach applied to tumor patient data.
Number of subjects: 2
Study: 29166184

Group type: EXPERIMENTAL
Intervention: Quarter prone position
Number of subjects: 15

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 15
Study: 26400262

Group type: COMPARATOR
Intervention: Protein mix (3×20 g/d) for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Protein mix
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pea protein, milk protein, egg-white protein
Number of subjects: 100

Group type: COMPARATOR
Intervention: Maltodextrin
Number of subjects: 100
Study: 22864510

Group type: EXPERIMENTAL
Intervention: Unloader knee orthosis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles (6° lateral wedge)
Number of subjects: 24
Study: 21312265

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d for 52 weeks
Number of subjects: 2302
Study: 19204233

Group type: EXPERIMENTAL
Intervention: Photographic bioimaging analysis of stromal keratitis
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Clinical measurements of stromal keratitis
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Necrotizing stromal keratitis
Number of subjects: 169
Study: 17406745

Group type: EXPERIMENTAL
Intervention: Gene expression profile assessment for adjuvant therapy decision
Number of subjects: 8000

Group type: COMPARATOR
Intervention: No adjuvant therapy based on gene expression profile
Number of subjects: 8000
Study: 14756386

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg capsule from Laboratório Teuto Brasileiro Ltd.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zoltec 150 mg capsule from Laboratórios Pfizer Ltd.
Number of subjects: 24
Study: 12463387

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 29
Study: 9728946

Group type: EXPERIMENTAL
Intervention: Apomorphine (dopaminergic stimulation)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 8081350

Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES), 45 min daily, 4 days a week for 3 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment (placebo control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 10
Study: 2529105

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ipratropium bromide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cromolyn sodium
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 782464

Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prednisone plus low-dose azathioprine and cyclophosphamide
Number of subjects: 14
Study: 31859735

Group type: EXPERIMENTAL
Intervention: Normative samples
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Alternative care
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: High-risk samples
Number of subjects: 714
Study: 28183580

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (propofol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inhalational anesthesia (volatile anesthetics)
Number of subjects: 40
Study: 26452162

Group type: EXPERIMENTAL
Intervention: Stapler hepatectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: CUSA resection
Number of subjects: 40
Study: 23565895

Group type: EXPERIMENTAL
Intervention: Bilateral training of both the seller and the buyer within a dyad
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Unilateral training of the seller
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Unilateral training of the buyer
Number of subjects: 360

Group type: COMPARATOR
Intervention: No-training control condition
Number of subjects: 360
Study: 22259246

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 22
Study: 18951818

Group type: EXPERIMENTAL
Intervention: Pregabalin 150-600 mg/day
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1174
Study: 17230434

Group type: EXPERIMENTAL
Intervention: Negative binomial model for treatment analysis
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Poisson regression
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Non-parametric methods
Number of subjects: 1465
Study: 15041086

Group type: EXPERIMENTAL
Intervention: Aware condition (objective monitoring)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unaware condition (no objective monitoring)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliant samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-compliant samples
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Afternoon sample (1600 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Last 3 days of sampling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekdays vs weekends
Number of subjects: 0
Study: 11331840

Group type: EXPERIMENTAL
Intervention: Dacron-patch closure
Number of subjects: 274

Group type: COMPARATOR
Intervention: Vein-patch closure
Number of subjects: 274
Study: 9218080

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 432

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 432
Study: 8110919

Group type: EXPERIMENTAL
Intervention: Slight Deviants (3% frequency change) presented in unattended input stream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Widely Deviants (5% frequency change) presented in unattended input stream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading condition with same stimuli
Number of subjects: 0
Study: 3333521

Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High salt diet
Number of subjects: 0
Study: 29409064

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 61

Group type: COMPARATOR
Intervention: Vardenafil (10 mg daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Adherent CPAP
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Adherent Vardenafil
Number of subjects: 61
Study: 26800181

Group type: EXPERIMENTAL
Intervention: Single centrifugation group (SCG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Double centrifugation group (DCG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 15
Study: 24334825

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 97
Study: 22172981

Group type: EXPERIMENTAL
Intervention: Category-cued recall task under divided attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Category-exemplar generation task following category judgment task
Number of subjects: 0
Study: 20589875

Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17604046

Group type: EXPERIMENTAL
Intervention: Group A (change rate of >=2 ECG stages per 2 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Group B (no rapid change)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Reocclusion cases
Number of subjects: 27
Study: 17162863

Group type: EXPERIMENTAL
Intervention: Tramadol (oral, two times a day) plus Tobradex and Diclofenac sodium eyedrops (four times a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobradex and Diclofenac sodium eyedrops (four times a day)
Number of subjects: 0
Study: 11869406

Group type: EXPERIMENTAL
Intervention: Telephone reminder one day prior to appointment
Number of subjects: 171

Group type: COMPARATOR
Intervention: Routine booking (no reminder)
Number of subjects: 171
Study: 10195531

Group type: EXPERIMENTAL
Intervention: 0.025 mg intrathecal morphine
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 0.05 mg intrathecal morphine
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 0.2 mg intrathecal morphine
Number of subjects: 143

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (systemic morphine)
Number of subjects: 143
Study: 7756098

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 400 mg three times daily for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1518268

Group type: EXPERIMENTAL
Intervention: 0.02 microM methotrexate (MTX) and 2 microM 6-mercaptopurine (6MP) combination treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous MTX (5 g/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous MTX followed by 6MP (1.3 g/m2)
Number of subjects: 0
Study: 4053513

Group type: EXPERIMENTAL
Intervention: Intravenous vasopressin (1‐3 mu‐units min‐1 kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (2.4 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Termination of vasopressin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin administration
Number of subjects: 0
Study: 30271161

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pitavastatin with sarpogrelate (PS)
Number of subjects: 72
Study: 27238052

Group type: EXPERIMENTAL
Intervention: Flowable bulk-filled resin composite (SDR)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Resin composite-only (Ceram X mono+)
Number of subjects: 86
Study: 26524515

Group type: EXPERIMENTAL
Intervention: Telephone-delivered Family Navigator services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23083704

Group type: EXPERIMENTAL
Intervention: Navigated total knee arthroplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 200
Study: 20810155

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 63
Study: 17932223

Group type: EXPERIMENTAL
Intervention: 9-h modified release formulation of UK-338,003
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15-h modified release formulation of UK-338,003
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colonic intubation of UK-338,003
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGP inhibition in mouse intestine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex vivo human distal intestine
Number of subjects: 0
Study: 16845959

Group type: EXPERIMENTAL
Intervention: Block anesthesia of nerve
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Supraperiosteal infiltration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Periodontal membrane injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intrapulpal injection
Number of subjects: 80
Study: 12786704

Group type: EXPERIMENTAL
Intervention: 0.25% sodium tetradecyl sulfate (STS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 72% glycerin
Number of subjects: 13
Study: 10985709

Group type: EXPERIMENTAL
Intervention: Early shock (< 24 h)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Late shock (≥ 24 h)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Early shock
Number of subjects: 815

Group type: COMPARATOR
Intervention: Late shock
Number of subjects: 815
Study: 7884505

Group type: EXPERIMENTAL
Intervention: Complete 99mTc-labeled anti-CEA IgG1 BW 431/26
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fragmented 99mTc-labeled anti-CEA F(ab')2/Fab' fragment mixture F023C5
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both complete and fragmented MAbs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Complete MAbs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fragmented MAbs
Number of subjects: 25
Study: 2238753

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 552298

Group type: EXPERIMENTAL
Intervention: Medigoxin (Lanitop) 300 microgram/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin (Lanoxin) 500 microgram/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medigoxin (Lanitop)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin (Lanoxin)
Number of subjects: 0
Study: 30107414

Group type: EXPERIMENTAL
Intervention: Evaluation of HRQoL using the SF-6D questionnaire
Number of subjects: 1893

Group type: EXPERIMENTAL
Intervention: Evaluation of HRQoL using SF-6D and SRH as an external standard
Number of subjects: 1893
Study: 28178721

Group type: EXPERIMENTAL
Intervention: Chemosaturation with percutaneous hepatic perfusion
Number of subjects: 91
Study: 25331108

Group type: EXPERIMENTAL
Intervention: Oral azithromycin 1 g daily for 3 days (group A)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo therapy (group B)
Number of subjects: 218
Study: 23042303

Group type: EXPERIMENTAL
Intervention: High adiponectin levels (Quartile 4)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Leptin
Number of subjects: 546

Group type: COMPARATOR
Intervention: Resistin
Number of subjects: 546
Study: 21488717

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 0
Study: 18377756

Group type: EXPERIMENTAL
Intervention: Conventional open repair
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Expertise-based RCT methodology
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Conventional RCT design
Number of subjects: 259
Study: 16701182

Group type: EXPERIMENTAL
Intervention: 4 paravertebral injections
Number of subjects: 69

Group type: COMPARATOR
Intervention: 1 paravertebral injection
Number of subjects: 69
Study: 12950041

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study: 10607686

Group type: EXPERIMENTAL
Intervention: Escalating Dose Regimen (EDR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bulk Dose Regimen (BDR)
Number of subjects: 48
Study: 9177597

Group type: EXPERIMENTAL
Intervention: Exercise group (walking three times a week for three months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (performing mental tasks with the same regularity)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 40
Study: 8274123

Group type: EXPERIMENTAL
Intervention: Plastic adhesive drape (drape group, n = 65)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No drape (no drape group, n = 55)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 3328638

Group type: EXPERIMENTAL
Intervention: Social work intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine treatment by GPs (Control)
Number of subjects: 80
Study: 31023487

Group type: EXPERIMENTAL
Intervention: Long‐chain omega-3 polyunsaturated fatty acids (LCn‐3PUFA) status (EPA + DHA, %,w/w)
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: DHA levels in overweight/obese females with diabetes
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: LCn‐3PUFA status
Number of subjects: 2092
Study: 30101519

Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (NAFL) treatment, 1540-nm, 40-50 mJ per microbeam, applied three times: immediately before surgery, at suture removal, and 6 weeks after surgery.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no laser treatment).
Number of subjects: 32
Study: 27871563

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) with 30 mL of 0.375% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous fentanyl (IVF) at 0.5 μg/kg body weight, repeated up to a maximum of 3 doses
Number of subjects: 60
Study: 23712823

Group type: EXPERIMENTAL
Intervention: VPT/CEM
Number of subjects: 407

Group type: COMPARATOR
Intervention: RCT
Number of subjects: 407
Study: 22541747

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg tablet formulation (test product)
Number of subjects: 72
Study: 20460711

Group type: EXPERIMENTAL
Intervention: Vinegar (acetic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18387728

Group type: EXPERIMENTAL
Intervention: GaAlAs laser (30 mW for 1 min)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dentin bonding agent
Number of subjects: 70
Study: 15755827

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with low phytate/low isoflavone (LP/LI)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with normal phytate/low isoflavone (NP/LI)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with low phytate/normal isoflavone (LP/NI)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with normal phytate/normal isoflavone (NP/NI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 55
Study: 12960540

Group type: EXPERIMENTAL
Intervention: Response to command during deep sedation with propofol and alfentanil
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Electroencephalographic monitoring (Bispectral Index)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Heart rate and responsiveness to command
Number of subjects: 56
Study: 10553738

Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine 600 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine 900 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/day (Gender effect)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine (all doses)
Number of subjects: 50
Study: 8889424

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 50
Study: 1802434

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6240223

Group type: EXPERIMENTAL
Intervention: norfloxacin (400 mg) twice daily for 10 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: trimethoprim-sulfamethoxazole (160-800 mg) twice daily for 10 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: norfloxacin
Number of subjects: 43

Group type: COMPARATOR
Intervention: trimethoprim-sulfamethoxazole
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: norfloxacin and trimethoprim-sulfamethoxazole
Number of subjects: 43
Study: 30833118

Group type: EXPERIMENTAL
Intervention: Parent-led physical activity program (4 days/week for 24 weeks, sessions lasting 25-45+ minutes)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Parent-led physical activity program (for those who increased MVPA)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 111
Study: 29743826

Group type: EXPERIMENTAL
Intervention: bilberry juice (BJ)
Number of subjects: 21

Group type: COMPARATOR
Intervention: energy‐matched control drink (PLA)
Number of subjects: 21
Study: 26845343

Group type: EXPERIMENTAL
Intervention: QMF149 (indacaterol acetate 150 μg/mometasone furoate 320 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indacaterol monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mometasone furoate monotherapy
Number of subjects: 0
Study: 24740596

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 6026

Group type: COMPARATOR
Intervention: Al(OH)3 control
Number of subjects: 6026
Study: 23036993

Group type: EXPERIMENTAL
Intervention: LoGIx diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: HiGIx diet
Number of subjects: 21
Study: 19950740

Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV) with PEEP of 5cm H2O
Number of subjects: 90

Group type: COMPARATOR
Intervention: Spontaneous Respiration (SR)
Number of subjects: 90
Study: 18457257

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) applied topically, 9000 AU NGF in 100 ml saline solution before operation and injections every other day for one month post-operation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group treated with normal saline solution
Number of subjects: 48
Study: 15368601

Group type: EXPERIMENTAL
Intervention: rhGH (recombinant human growth hormone)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11248285

Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg subcutaneous administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tinzaparin-like LMWH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tinzaparin and Tinzaparin-like LMWH
Number of subjects: 30